{"id":"W4231121000","doi":"10.1200/jco.2019.37.15_suppl.tps4155","title":"Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Oncology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003750395,0.0002971846,0.002804388,0.0001800417,0.0001032551,0.00003719598,0.000456948,0.0001625647,0.00007725805],"category_scores_gemma":[0.002167217,0.0001446458,0.0002253518,0.0004168432,0.0002802949,0.0003046877,0.0001287371,0.001109111,0.00000953813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002039257,"about_ca_system_score_gemma":0.001478166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000664765,"about_ca_topic_score_gemma":0.0005118045,"domain_scores_codex":[0.9949403,0.001025813,0.002628623,0.0003913188,0.0006846277,0.0003292646],"domain_scores_gemma":[0.9928226,0.003698916,0.001871312,0.0005033928,0.0008697429,0.0002340002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8116246,0.01321295,0.153739,0.00001887006,0.001087846,0.0001154919,0.001171381,0.00004233587,0.000008159505,0.000007661441,0.0001693332,0.01880239],"study_design_scores_gemma":[0.7215205,0.08508559,0.1903575,0.0001403048,0.000954774,0.00001321555,0.001024599,0.0001081262,0.000007354612,0.000004086346,0.0006511427,0.0001327383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985787,0.0008962867,0.0000559523,0.002713253,0.001144916,0.008523857,0.000007737171,0.000008524141,0.0008624594],"genre_scores_gemma":[0.9963174,0.0001424584,0.002059704,0.0007340659,0.0003299691,0.0002285039,0.00001506973,0.00003234765,0.0001404682],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09010407,"threshold_uncertainty_score":0.5898486,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1155206016949348,"score_gpt":0.4541062629948091,"score_spread":0.3385856612998743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}